EMA Authorised: Hexyon (filamentous haemagglutinin;Haemophilus influenzae type B polysaccharide (polyribosylribitol phosphate);hepatitis B surface antigen;pertussis toxoid;poliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cells;poliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cells;poliovirus (inactivated) type 3 (Saukett strain) produced on Vero cells;tetanus protein;tetanus toxoid adsorbed on aluminium hydroxide, hydrated;Diphtheria toxoid) — Sanofi Winthrop Industrie

View source ↗

Summary

EMA authorised Hexyon, a hexavalent vaccine combining protection against hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type b meningitis, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Meningitis
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Hexyon (Hexavalent vaccine (DTP-HBV-Hib-IPV))

Snippet

Status: Authorised. Therapeutic area: Hepatitis B;Tetanus;Immunization;Meningitis, Haemophilus;Whooping Cough;Poliomyelitis;Diphtheria. MAH: Sanofi Winthrop Industrie. Decision date: 26/09/2025